These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11404194)

  • 1. Retreatment with interferon-alpha at dosages or period increased by 1.3 times is effective for treatment for transient responders and non-responders in chronic hepatitis C patients.
    Okanoue T; Daimon Y; Kirishima T; Ohnishi N; Nakamura H; Nagao Y; Minami M; Itoh Y
    Hepatol Res; 2001 Jul; 20(3):348-358. PubMed ID: 11404194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients.
    Okanoue T; Itoh Y; Kirishima T; Daimon Y; Toyama T; Morita A; Nakajima T; Minami M
    Hepatol Res; 2002 May; 23(1):62-77. PubMed ID: 12084557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
    J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of interferon retreatment on interferon-resistant patients with chronic hepatitis C.
    Egusa K; Kondo J
    Acta Med Okayama; 2003 Jun; 57(3):151-8. PubMed ID: 12908013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Vicari F; Idéo G
    J Viral Hepat; 1997 May; 4(3):185-91. PubMed ID: 9181527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.
    Melian EB; Plosker GL
    Drugs; 2001; 61(11):1661-91. PubMed ID: 11577799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.
    Cammà C; Bruno S; Schepis F; Lo Iacono O; Andreone P; Gramenzi AG; Mangia A; Andriulli A; Puoti M; Spadaro A; Freni M; Di Marco V; Cino L; Saracco G; Chiesa A; Crosignani A; Caporaso N; Morisco F; Rumi MG; Craxì A
    Gut; 2002 Dec; 51(6):864-9. PubMed ID: 12427791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tokuda A; Horiguchi Y; Nakano H; Honda T; Nakano S; Hayashi K; Katano Y; Nakano I; Hayakawa T; Nishimura D; Kato K; Imada K; Imoto M; Fukuda Y;
    J Viral Hepat; 2000 Nov; 7(6):414-9. PubMed ID: 11115052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
    Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
    J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose interferon alpha-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response.
    Bellary S; Smith DG; Bankes P; Harris A; Shayiq R; Black M
    Am J Gastroenterol; 1995 Feb; 90(2):259-62. PubMed ID: 7847297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Hisanaga Y
    Cancer; 2000 Jan; 88(1):58-65. PubMed ID: 10618606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus interferon: a novel interferon for the treatment of hepatitis C.
    Heathcote J
    J Viral Hepat; 1998 Sep; 5 Suppl 1():13-8. PubMed ID: 9795924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C.
    Toyoda H; Kumada T; Hayashi K; Honda T; Morita K; Nishimura D; Imada K; Imoto M; Horiguchi Y; Nakano H; Nakano I; Fukuda Y;
    Cancer Detect Prev; 2003; 27(6):498-502. PubMed ID: 14642559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.